291 related articles for article (PubMed ID: 28074905)
1. MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway.
Fang C; Chen YX; Wu NY; Yin JY; Li XP; Huang HS; Zhang W; Zhou HH; Liu ZQ
Sci Rep; 2017 Jan; 7():40384. PubMed ID: 28074905
[TBL] [Abstract][Full Text] [Related]
2. miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1.
Deng H; Qianqian G; Ting J; Aimin Y
Biomed Pharmacother; 2018 Oct; 106():1072-1081. PubMed ID: 30119173
[TBL] [Abstract][Full Text] [Related]
3. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S
EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
[TBL] [Abstract][Full Text] [Related]
4. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
5. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
Qi MM; Ge F; Chen XJ; Tang C; Ma J
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
[TBL] [Abstract][Full Text] [Related]
6. eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27Kip1 translation.
Zhang Y; Yu JJ; Tian Y; Li ZZ; Zhang CY; Zhang SF; Cao LQ; Zhang Y; Qian CY; Zhang W; Zhou HH; Yin JY; Liu ZQ
Oncotarget; 2015 Sep; 6(28):25441-51. PubMed ID: 26213845
[TBL] [Abstract][Full Text] [Related]
7. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1.
Cheng R; Lu C; Zhang G; Zhang G; Zhao G
Oncol Rep; 2017 Apr; 37(4):2129-2136. PubMed ID: 28350100
[TBL] [Abstract][Full Text] [Related]
10. Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
Huang J; Lin C; Dong H; Piao Z; Jin C; Han H; Jin D
Cancer Chemother Pharmacol; 2020 Nov; 86(5):663-672. PubMed ID: 33030583
[TBL] [Abstract][Full Text] [Related]
11. Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy.
Ma Y; Yuwen D; Chen J; Zheng B; Gao J; Fan M; Xue W; Wang Y; Li W; Shu Y; Xu Q; Shen Y
Int J Nanomedicine; 2019; 14():8121-8132. PubMed ID: 31632022
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
Shi L; Xu Z; Wu G; Chen X; Huang Y; Wang Y; Jiang W; Ke B
BMC Cancer; 2017 Feb; 17(1):138. PubMed ID: 28202053
[TBL] [Abstract][Full Text] [Related]
13. MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFβR1/Smad signaling pathway in NSCLC.
Wang X; Chen X; Meng Q; Jing H; Lu H; Yang Y; Cai L; Zhao Y
Sci Rep; 2015 Dec; 5():17618. PubMed ID: 26620926
[TBL] [Abstract][Full Text] [Related]
14. SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer.
Jiao P; Hou J; Yao M; Wu J; Ren G
Biomed Pharmacother; 2019 Sep; 117():109164. PubMed ID: 31252267
[TBL] [Abstract][Full Text] [Related]
15. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer.
Zhao J; Fu W; Liao H; Dai L; Jiang Z; Pan Y; Huang H; Mo Y; Li S; Yang G; Yin J
BMC Cancer; 2015 Oct; 15():731. PubMed ID: 26482648
[TBL] [Abstract][Full Text] [Related]
16. Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1α mediated XPC transcription.
Liu Y; Wang X; Li W; Xu Y; Zhuo Y; Li M; He Y; Wang X; Guo Q; Zhao L; Qiang L
Oncogene; 2020 Nov; 39(45):6893-6905. PubMed ID: 32978517
[TBL] [Abstract][Full Text] [Related]
17. LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway.
Xu L; Xu Y; Yang M; Li J; Xu F; Chen BL
BMC Pulm Med; 2020 Oct; 20(1):266. PubMed ID: 33059643
[TBL] [Abstract][Full Text] [Related]
18. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
[TBL] [Abstract][Full Text] [Related]
19. MiRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC.
Jiang Z; Yin J; Fu W; Mo Y; Pan Y; Dai L; Huang H; Li S; Zhao J
PLoS One; 2014; 9(4):e94639. PubMed ID: 24722426
[TBL] [Abstract][Full Text] [Related]
20. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
